| DRUG WATCH |
|
| Year : 2014 | Volume
: 46
| Issue : 5 | Page : 553-554 |
Factor XI deficiency diagnosed following use of adalimumab
Guven Cetin1, Cumali Karatoprak2, Muharrem Kiskac2, Mehmet Zorlu2, Aylin Rezvani3, Mehmet Ali Cikrikcioglu2
1 Department of Hematology, Bezmialem Vakif University, Faculty of Medicine, Fatih, Istanbul, Turkey
2 Internal Medicine Clinic, Bezmialem Vakif University, Faculty of Medicine, Fatih, Istanbul, Turkey
3 Department of Physical Medicine and Rehabilitation, Bezmialem Vakif University, Faculty of Medicine, Fatih, Istanbul, Turkey
Correspondence Address:
Cumali Karatoprak
Internal Medicine Clinic, Bezmialem Vakif University, Faculty of Medicine, Fatih, Istanbul
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.140596
Adalimumab is a drug used in the treatment of refractory psoriasis. We present a case of a 55-year-old male patient who developed petechiae and purpura after the ninth dose of adalimumab therapy. The results of laboratory investigations revealed factor XI (F.XI) deficiency. It should be recognized that F XI deficiency may develop in patients using long-term adalimumab, leading to increased risk of bleeding.
[FULL TEXT] [PDF]*
|
